鼻咽癌远处转移及预后的相关因素

doi:10.3760/cma.j.issn.1673-422X.2014.02.008

摘要/Abstract

摘要： 远处转移是鼻咽癌（NPC）治疗失败的主要原因。患者临床相关因素如年龄、性别、肿瘤分期等可影响鼻咽癌远处转移及预后。NPC远处转移的分子标志物包括EB病毒DNA、p53、表皮生长因子受体和血管内皮生长因子，其有望成为NPC预后的生物学指标。另外，病理分型和治疗手段也是NPC预后的影响因素。

关键词: 鼻咽肿瘤, 肿瘤转移, 预后

Abstract: Distant metastasis is the main cause of treatment failure in nasopharyngeal carcinoma (NPC). Clinical relevant factors such as age, gender, tumor staging can affect the distant metastasis and prognosis of NPC. Molecular markers of NPC distant metastasis include EB virus DNA, p53, epidermal growth factor receptor and vascular endothelial growth factor, which are expected to become the biological indicators of NPC prognosis. In addition, the pathological classification and the treatment means are also the affecting factors for NPC prognosis.

Key words: Nasopharyngeal neoplasms, Neoplasm metastasis, Prognosis

张汉文, 彭逊. 鼻咽癌远处转移及预后的相关因素[J]. 国际肿瘤学杂志, 2014, 41(2): 103-106.

Zhang Hanwen, Peng Xun. Factors related to distant metastasis and prognosis of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2014, 41(2): 103-106.

参考文献

［1］ Sultan I, Casanova M, Ferrari A, et al. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study［J］. Pediatr Blood Cancer, 2010, 55(2): 279-284. ［2］ Han F, Zhao C, Huang SM, et al. Longterm outcomes and prognostic factors of reirradiation for locally recurrent nasopharyngeal carcinoma using intensitymodulated radiotherapy［J］. Clin Oncol (R Coll Radiol), 2012, 24(8): 569-576. ［3］ Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area［J］. Eur J Cancer, 2012, 48(6): 882-888. ［4］ Xiao G, Cao Y, Qiu X, et al. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma［J］. BMC Cancer, 2013, 13(1): 226. ［5］ Lu X, Wang FL, Guo X, et al. Favorable prognosis of female patients with nasopharyngeal carcinoma［J］. Chin J Cancer, 2013, 32(5): 283-288. ［6］ Pan J, Tang T, Xu L, et al. Prognostic significance of expression of cyclooxygenase2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma［J］. Head Neck, 2013, 35(9): 1238-1247. ［7］ Liu F, Xiao JP, Xu GZ, et al. Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma［J］. Radiat Oncol, 2013, 8(1): 157. ［8］ Lai SZ, Li WF, Chen L, et al. How does intensitymodulated radiotherapy versus conventional twodimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?［J］. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661-668. ［9］ Xu L, Pan J, Wu J, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break［J］. Radiother Oncol, 2010, 96(1): 94-99. ［10］ Mao YP, Li WF, Chen L, et al. A clinical verification of the Chinese 2008 staging system for nasopharyngeal carcinoma［J］. Ai Zheng, 2009, 28(10): 1022-1028. ［11］ Pan CC, Lu J, Yu JR, et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: a study of 1027 cases and review of the literature［J］. Exp Ther Med, 2012, 4(2): 334-338. ［12］ Peng X, Chen S, Du C, et al. Clinical features and prognostic factors in patients with nasopharyngeal carcinoma relapse after primary treatment［J］. Head Neck Oncol, 2013, 5(2): 21. ［13］ Pan C, Wu P, Yu J, et al. CTguided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma［J］. Int J Hyperthermia, 2011, 27(6): 549-554. ［14］ Wang HY, Sun BY, Zhu ZH, et al. Eightsignature classifier for prediction of nasopharyngeal ［corrected］ carcinoma survival［J］. J Clin Oncol, 2011, 29(34): 4516-4525. ［15］ Cai MB, Han HQ, Bei JX, et al. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma［J］. Int J Biol Sci, 2012, 8(6): 891-900. ［16］ Xie X, Wang H, Jin H, et al. Expression of pAkt affects p53 codon 72 polymorphismbased prediction of response to radiotherapy in nasopharyngeal carcinoma［J］. Radiat Oncol, 2013, 8(1): 117. ［17］ Zhang R, Zhao Y, Zhang S, et al. The expressions of EphrinB2 and VEGF in nasopharyngeal carcinoma and their clinical significance［J］. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2013, 27(4): 178-180. ［18］ Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma EpsteinBarr virus DNA analysis in a surveillance program［J］. Cancer, 2013, 119(10): 1838-1844. ［19］ Chai SJ, Pua KC, Saleh A, et al. Clinical significance of plasma EpsteinBarr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma［J］. J Clin Virol, 2012, 55(1): 34-39. ［20］ Lai SZ, Li WF, Chen L, et al. How does intensitymodulated radiotherapy versus conventional twodimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?［J］. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661-668. ［21］ Lin S, Pan J, Han L, et al. Nasopharyngeal carcinoma treated with reducedvolume intensitymodulated radiation therapy: report on the 3year outcome of a prospective series［J］. Int J Radiat Oncol Biol Phys, 2009, 75(4): 1071-1078. ［22］ Ouyang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by metaanalysis of published literaturebased randomized, controlled trials［J］. Ann Oncol, 2013, 24(8): 2136-2146. ［23］ Ji X, Xie C, Hu D, et al. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(2): e56208. ［24］ Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrentadjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma［J］. J Natl Cancer Inst, 2010, 102(15): 1188-1198. ［25］ Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial［J］. Lancet Oncol, 2012, 13(2): 163-171. ［26］ Liang ZG, Zhu XD, Zhou ZR, et al. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a metaanalysis of 793 patients from 5 randomized controlled trials［J］. Asian Pac J Cancer Prev, 2012, 13(11): 5747-5752. ［27］ Ma BB, Kam MK, Leung SF, et al. A phase Ⅱ study of concurrent cetuximabcisplatin and intensitymodulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma［J］. Ann Oncol, 2012, 23(5): 1287-1292. ［28］ Chen CY, Zhao C, Gao L, et al. An openlabeled, multicentric clinical study of cetuximab combined with intensitymodulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): a 2year followup report［J］. J Clin Oncol, 2012, 30 Suppl: 5535. ［29］ Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multiinstitutional trial［J］. Lancet Oncol, 2012, 13(2): 172-180.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[7]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[8]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[9]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[15]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.